Press "Enter" to skip to content

FDA Places Clinical Hold On Denali's Alzheimer's Potential Program

The FDA has issued a clinical hold on Denali Therapeutics Inc’s (NASDAQ: DNLI) Investigational New Drug (IND) application for DNL919 (ATV:TREM2).

  • TREM2 is a protein expressed in microglia, the brain’s resident immune cells. 
  • Mutations in the TREM2 gene are strongly associated with neuroinflammation and an increased risk for Alzheimer’s disease.
  • Related content: Benzinga’s Full FDA Calendar
  • ATV:TREM2 is an antibody designed to modulate TREM2 and thereby normalize microglial function 
  • The FDA agency will provide an official clinical hold letter to Denali in approximately 30 days. 
  • Denali plans to provide additional updates pending discussion with the FDA.
  • Price Action: DNLI shares are down 14.20% at $33.07 during the market session on the last check Thursday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *